Jcog0210
Web16 nov 2024 · Background Specific treatment strategies are sorely needed for scirrhous-type gastric cancer still, which has poor prognosis. Based on the promising results of our … Web18 giu 2014 · Phase II study of preoperative chemotherapy with S-1 and cisplatin followed by gastrectomy for clinically resectable type 4 and large type 3 gastric cancers (JCOG0210). J Surg Oncol. 2013; 107 : 741-745
Jcog0210
Did you know?
WebBackground and objectives: We conducted a phase II study to evaluate the safety and efficacy of preoperative chemotherapy with S-1 + cisplatin followed by gastrectomy in … Web5 mar 2024 · Based on the positive results of JCOG0210, JCOG conducted a phase III study to confirm the efficacy of NAC in patients with linitis plastica (type 4) and large (≥8 …
WebMethods: Previously, Japan Clinical Oncology Group (JCOG) had conducted 3 phase II trials to evaluate NAC with irinotecan/CDDP (JCOG0001) and S-1/CDDP (JCOG0405) for extensive nodal disease, and with S-1/CDDP (JCOG0210) for large type 3 and type 4 (linitis plastica) disease. Background: Specific treatment strategies are sorely needed for scirrhous-type gastric cancer still, which has poor prognosis. Based on the promising results of our previous phase II study (JCOG0210), we initiated a phase III study to confirm the efficacy of neoadjuvant chemotherapy (NAC) in type 4 or large type 3 gastric cancer.
Web13 dic 2011 · In a preoperative setting, phase II study of S-1 plus cisplatin for the patients with locally advanced gastric cancer (JCOG0210) showed 48% of pathological response … Web1 giu 2010 · Phase II study of preoperative chemotherapy with S-1 and cisplatin followed by gastrectomy for clinically resectable type 4 and large type 3 gastric cancers (JCOG0210). Iwasaki Y , Sasako M , Yamamoto S , Nakamura K , Sano T , Katai H , Tsujinaka T , Nashimoto A , Fukushima N , Tsuburaya A , Gastric Cancer Surgical Study Group of …
Web2 lug 2024 · The proportion of patients with CY1 in the JCOG0210 and the JCOG0501 trials which included patients with type 4 or large type 3 tumors was 30% (diagnosed after NAC) and 21%, respectively. CY1 has been regarded as a worse prognostic factor in patients with gastric cancer [ 13 , 14 ].
Web1 mag 2024 · This study aimed to clarify the significance of splenectomy (Sp) for upper gastric carcinoma with invasion to the greater curvature. The Japan Clinical Oncology Group (JCOG) conducted a phase III randomized clinical trial (JCOG 0110), where the significance of Sp in total gastrectomy (TG) for upper gastric carcinoma without invasion … marketplace chinoiseWebSee PDF Section Below. The ASCO JKF8210G002,120/60,110/50 is a 2/2 normally closed general service solenoid valve with a 1/2 inch pipe size, 120/60,110/50 Hz voltage, brass … marketplace chineWeb1 feb 2024 · Based on the promising results of our previous phase II study (JCOG0210), we initiated a phase III study to confirm the efficacy of neoadjuvant chemotherapy (NAC) in type 4 or large type 3 gastric ... marketplace chiropracticWeb1 giu 2013 · In JCOG0210, patients received CS chemotherapy followed by surgery; this trial showed a good 3-year survival rate of 24.5% [3]; thus, the next phase III study … marketplace chiropractic lake stevensWeb3 set 2013 · Patient population. We included all eligible patients from two clinical trials (JCOG0210 and JCOG0405) that were conducted by the JCOG. These phase II trials … navigate to gilligan\u0027s seafood goose creekWebGiven the promising results of our previous phase II study evaluating neoadjuvant chemotherapy (NAC) with S-1 plus cisplatin (JCOG0210), we performed a phase III … navigate to gas stationhttp://www.jcog.jp/document/s_0501.pdf navigate to goodwill